RNF187 Inhibitors
Chemical inhibitors of RNF187 can modulate the protein's function by interfering with the proteolytic pathway essential for protein turnover and homeostasis within the cell. MG132, as a proteasome inhibitor, can directly prevent the degradation of proteins that RNF187 marks for turnover, which leads to an accumulation of these proteins within the cell. Similarly, Lactacystin can exert its inhibitory effect by specifically targeting the proteasome, thereby causing a buildup of substrates that RNF187 would typically help degrade. Epoxomicin, another proteasome inhibitor, can irreversibly bind to the proteasome, thus disrupting the normal function of RNF187 in the ubiquitin-proteasome system. This binding results in the stabilization of proteins that would otherwise be degraded. Bortezomib and Carfilzomib, both dipeptide boronic acid analogs and epoxyketone-based inhibitors, respectively, can also lead to the accumulation of polyubiquitinated proteins by inhibiting the 26S proteasome, thereby impeding RNF187's ability to regulate protein degradation.
Furthermore, Ixazomib and its biologically active form MLN2238 can inhibit the proteasome's activity, resulting in the accumulation of ubiquitinated proteins, which in turn can block the functional role of RNF187 in protein catabolism. Marizomib, being a naturally occurring inhibitor, can bind to the proteasome irreversibly, preventing the degradation of proteins and hence indirectly inhibiting RNF187. Oprozomib, another oral proteasome inhibitor, can accumulate proteins targeted by RNF187, disrupting its normal function. Delanzomib functions in a similar manner by blocking the proteolytic breakdown that RNF187 initiates. CEP-18770 can also inhibit the proteasome reversibly, leading to a buildup of substrates of RNF187. Lastly, NPI-0052, found in a marine bacterium, can inhibit the 20S proteasome, resulting in the accumulation of proteins marked for degradation by RNF187, thereby reducing the efficacy of RNF187's role in protein turnover. Each of these inhibitors, by stalling the proteasome's activity, can interfere with the function of RNF187, highlighting their significant role in modulating the protein's activity within the ubiquitin-proteasome pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a potent, reversible, and cell-permeable proteasome inhibitor. RNF187, as an E3 ubiquitin-protein ligase, tags proteins for degradation via the ubiquitin-proteasome pathway. By inhibiting the proteasome, MG132 can lead to an accumulation of proteins that RNF187 would normally help degrade, effectively reducing RNF187's functional impact on protein turnover. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome. Similar to MG132, it impedes the degradation of proteins that RNF187 would target for ubiquitination, thus indirectly inhibiting RNF187's role in protein catabolism by preventing the downstream effects of its E3 ligase activity. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective and irreversible proteasome inhibitor. It covalently binds and inhibits the chymotrypsin-like activity of the proteasome, leading to the accumulation of proteins destined for degradation. This accumulation indirectly inhibits RNF187 by interfering with the intended outcome of its E3 ligase function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a dipeptide boronic acid analog that inhibits the 26S proteasome. By disrupting the proteasomal degradation pathway, bortezomib causes an indirect inhibition of RNF187 by allowing substrates of RNF187 to accumulate and thereby negate its regulatory effects on protein degradation. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is an epoxyketone-based proteasome inhibitor that irreversibly binds to and inhibits the proteasome's activity. This inhibition leads to a buildup of polyubiquitinated proteins, which in turn indirectly inhibits RNF187 by stalling the degradation process it facilitates. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a small molecule proteasome inhibitor. By inhibiting the proteasome, it prevents the degradation of proteins ubiquitinated by RNF187, indirectly reducing RNF187's role in protein homeostasis. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an oral proteasome inhibitor that, by inhibiting the proteasome, leads to an accumulation of proteins that RNF187 would normally target for ubiquitination and degradation, indirectly inhibiting the function of RNF187. | ||||||
UCH-L1 Inhibitor Inhibitor | 668467-91-2 | sc-356182 | 10 mg | $204.00 | 1 | |
Delanzomib is a proteasome inhibitor that blocks the degradation of polyubiquitinated proteins, leading to an indirect inhibition of RNF187 by preventing the proteolytic activity that RNF187 is meant to initiate. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
CEP-18770 is a reversible proteasome inhibitor that, by blocking the proteolytic breakdown of proteins, indirectly inhibits RNF187's ability to regulate protein degradation through ubiquitination. | ||||||